Although approximately only one-third of SSc patients shows an inflammatory gene expression profile in fibrotic skin or presents with clinical features of inflammation57–60, inhibition of inflammation may contribute to the efficacy of STAT3 inhibitors in particular in the inflammatory subset of patients. The gene discussed is STAT3; the disease is systemic sclerosis.